Doug Macron Contributor Phone +1-215-348-9836 Email [email protected] Doug covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies for GenomeWeb. Breaking News Abbisko Therapeutics Launches Phase I Trial of FGFR2/3 Inhibitor for Solid Tumors Structural Variant Study Points to Pediatric Glioma Drivers, Prognostic Features Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials Turnstone, Moffitt Cancer Center Get FDA Permission to Study TIL Therapy in Melanoma Patients Guardant Health Licenses Genomic Cancer Assays to Adicon for Testing in China Bio-Techne Nabs CE Mark for HPV Head and Neck Cancer Test, Completes Namocell Acquisition
